{"id":296217,"date":"2026-10-08T00:00:00","date_gmt":"2026-10-08T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0048-2024-biopharma-scleroderma-systemic-sclerosis-current-treatment-treatment-algorithms\/"},"modified":"2026-10-19T11:00:44","modified_gmt":"2026-10-19T11:00:44","slug":"algoim0048-2026-biopharma-scleroderma-systemic-sclerosis-current-treatment-treatment-algorithms-claims-data-analysis","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0048-2026-biopharma-scleroderma-systemic-sclerosis-current-treatment-treatment-algorithms-claims-data-analysis\/","title":{"rendered":"Scleroderma (Systemic Sclerosis) &#8211; Current Treatment &#8211; Treatment Algorithms: Claims Data Analysis &#8211; Scleroderma (Systemic Sclerosis) (US)"},"content":{"rendered":"<p>Scleroderma (systemic sclerosis, <abbr data-abbreviation-entity=\"6793\" title=\"systemic sclerosis\">SSc<\/abbr>) is a rare, progressive autoimmune disease marked by skin fibrosis, systemic inflammation, and vasculopathy, leading to Raynaud\u2019s phenomenon and painful digital ulcers. Severe complications, including <abbr data-abbreviation-entity=\"6793\" title=\"systemic sclerosis\">SSc<\/abbr>-related pulmonary arterial hypertension, interstitial lung disease, and renal crisis, contribute to high mortality. Treatment largely involves generics and off-label therapies targeting diverse symptoms, with Boehringer Ingelheim\u2019s Ofev (nintedanib) and Roche \/ Genentech\u2019s Actemra (tocilizumab) being the only <abbr data-abbreviation-entity=\"4817\" title=\"Food and Drug Administration\">FDA<\/abbr>-approved options. This report analyzes real-world U.S. claims data to reveal current prescribing patterns and highlight unmet needs and opportunities for emerging players in the <abbr data-abbreviation-entity=\"6793\" title=\"systemic sclerosis\">SSc<\/abbr> market.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What patient shares do key therapies and brands garner by line of therapy in newly diagnosed <abbr data-abbreviation-entity=\"6793\" title=\"systemic sclerosis\">SSc<\/abbr> patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed <abbr data-abbreviation-entity=\"6793\" title=\"systemic sclerosis\">SSc<\/abbr> patients?<\/li>\n<li>How have Ofev and Actemra been integrated into the treatment algorithm, and what are their sources of business?<\/li>\n<li>What percentage of <abbr data-abbreviation-entity=\"6793\" title=\"systemic sclerosis\">SSc<\/abbr> patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?<\/li>\n<li>What percentage of <abbr data-abbreviation-entity=\"6793\" title=\"systemic sclerosis\">SSc<\/abbr> patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients?<\/li>\n<\/ul>\n<p><b>Geography: <\/b>United States<\/p>\n<p><strong>Key drugs covered: <\/strong>Ofev, Actemra, select other biologics (e.g., rituximab)<\/p>\n<p><strong>Product description: <\/strong>Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Understand patient flow between lines of therapy.<\/li>\n<li>Evaluate your brand share against competitors.<\/li>\n<li>Accurately assess your source of business.<\/li>\n<li>Quantify opportunities at different stages of the treatment algorithm.<\/li>\n<\/ul>\n<p><strong>Product enhancement: <\/strong>Treatment Algorithms: Claims Data Analysis leverages Clarivate\u2019s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.<\/p>\n","protected":false},"template":"","class_list":["post-296217","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-rheumatology","biopharma-therapy-areas-scleroderma-systemic-sclerosis","biopharma-product-current-treatment","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296217","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=296217"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}